Table 1 Demographics, disease characteristics and medication of the study group

No. of patients

28

Female sex (%)

13 (46)

Age, y (median, range)

64 (37–83)

BMI (mean, SD)

24 (3.6)

History of diabetes (%)

12 (39)

Dialysis vintage, month (median, range)

10 (3–94)

Dialysis modality (PD/HD) (%)

50/50

Laboratory parameters

 fS-calcium-ion 1.16 mmol/l − 1.30 mmol/l (mean, SD))

1.17 (0.08)

 fP-phosphorus 0.71–1.23 mmol/l (median, IQR)

1.69 (0.49)

 fP-iPTH 15–65 ng/l (median, IQR)

285 (185–520)

 P- D-25 > 50 nmol/l (median, IQR)

70 (44–91)

 S- D- 1,25 37–216 pmol/l (median, IQR)

30 (24–55)

CAC score (median, IQR)

366 (111–656)

Bone histomorphometry

 High turnover/hyperparathyreoid bone disease

11 (42)

 Normal turnover/mild hyperparathyroid bone disease

9 (35)

 Low turnover/adynamic bone disease

6 (23)

Medication

 Alfacalcidol, Paricalcitol (%)

18 (64)

 Calcium carbonate (%)

24 (86)

 Calcimimetic (%)

4 (14)

 Cholecalciferol (%)

25 (89)

 Sevelamer/lantane carbonate (%)

17 (60)